# Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

> **NCT05280470** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 187 (actual)

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** Ifinatamab Deruxtecan (I-DXd)

## Key facts

- **NCT ID:** NCT05280470
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-09
- **Primary completion:** 2025-03-03
- **Final completion:** 2026-12-15
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05280470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05280470, "Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05280470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*